Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carregado – page 19

669 clinical trials in Carregado, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carregado at a glance
669
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

669 trials in Carregado

Open in trial search

Study on the Safety and Effects of UX701 Gene Therapy for Adults with Wilson Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Asthma

Recruiting

Study on the Effectiveness and Safety of Indacaterol Acetate/Mometasone Furoate vs. Budesonide for Children Aged 6-11 with Asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Novartis Pharma AG

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:University College London

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carregado

What the registry says about research in the country

01 Nephrology Research

Research focusing on secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. Clinical studies aim to evaluate new therapeutic approaches for managing hormone levels in patients with end-stage kidney disease (ESKD).

  • Hormone regulation in dialysis patients
  • SHPT treatment optimization
  • Renal replacement therapy outcomes

Studies evaluate novel treatments' efficacy in reducing parathyroid hormone levels in dialysis patients.

02 Cardiovascular Research

Investigations into atherosclerotic cardiovascular disease among dialysis patients, with particular focus on inflammatory markers. Studies examine the relationship between kidney disease and cardiovascular complications.

  • Cardiovascular outcomes in ESKD
  • Inflammatory biomarkers
  • Dialysis-related cardiovascular complications

Research aims to assess new treatments targeting inflammation in dialysis patients with cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.